Posts

When Your PSA Number Tells Only Part of the Story

Image
Tumor Prostate‐Specific Antigen Density Can Predict Tumor Aggressiveness and Heterogeneity in Prostate Cancer - Yang - The Prostate - Wiley Online Library Informed Prostate Cancer Support Group (IPCSG) Newsletter A New Measure Called "Tumor PSA Density" May Reveal Hidden Aggression Research Report • March 2026 Bottom Line Up Front (BLUF) A newly published study introduces a refined measurement called Tumor PSA Density (TPSAD) — calculated by dividing your serum PSA density by the actual MRI-measured tumor volume — that can more accurately predict whether a prostate tumor is aggressive and molecularly complex (heterogeneous) than standard PSA alone. Men with a low TPSAD had significantly larger, more aggressive tumors, more frequent loss of key tumor-suppressor genes, and shorter time to PSA recurrence after surgery. In contrast, men with a high TPSAD tended to have smaller, more localized, and molecularly simpler cancers. This research fits ...
Post a Comment
Read more

UC Berkley Finds New Molecular Glue Which May Stick Where Zytiga and Xtandi Fail

Image
An Optimized RNF126-Targeting Covalent Handle for Molecular Glue Degraders | bioRxiv Informed Prostate Cancer Support Group (IPCSG)  ·  Educational Newsletter A "Molecular Glue" Approach That May Finally Crack the AR-V7 Code March 2026  |  Research Update  |  Advanced & Castration-Resistant Prostate Cancer Bottom Line Up Front (BLUF) Scientists at UC Berkeley have engineered a safer, more refined version of a so-called "molecular glue" compound that can simultaneously destroy both the standard androgen receptor (AR) and its dangerous drug-resistant cousin, AR-V7, in prostate cancer cells. Unlike enzalutamide (Xtandi) or the PROTAC drug ARV-110 (avdegalutamide)—which cannot touch AR-V7—this new laboratory compound, called EST1140, works by recruiting a cellular "trash-disposal" protein called RNF126 to tag both AR and AR-V7 for destruction. While still in early laboratory (pre-clinical) rese...
Post a Comment
Read more

Teaching Cancer Cells to Remember Who They Used to Be:

Image
This image shows patient derived tumor organoids before (top) and after treatment (bottom).  The colors show the activation of pathways related to cell differentiation in cancer stem cells.  Shortly after these images were taken, the cancer stem cells spontaneously collapsed.  Photo credit: Pradipta Ghosh/HUMANOID What the New Science of Cancer Reversion Means for Prostate Cancer Patients Breakthrough studies from Korea and San Diego have demonstrated that cancer cells can be reprogrammed back toward normality — not killed, but re-educated. The implications for prostate cancer patients — from newly diagnosed to late-stage mCRPC — are potentially profound.   Special Science Update — March 2026 Prepared by the IPCSG Educational Committee   Bottom Line Up Front  A cluster of recent studies — led by researchers at KAIST in South Korea and UC San Diego — has demonstrated that cancer cells can be systemati...
Post a Comment
Read more

Plastics Inside the Prostate:

Image
Microplastics found in 90% of prostate cancer tumors, study reveals | ScienceDaily What the Latest Research Tells Us About Microplastics and Prostate Cancer A growing body of evidence links tiny plastic particles found inside human tumors to potential cancer risk — but scientists urge caution about overstating a still-early finding. February 28, 2026 Bottom Line Up Front (BLUF) Two independent research teams — one at NYU Langone Health (February 2026) and one at Peking University (September 2024) — have detected microplastics inside prostate tumors at concentrations roughly 1.5 to 2.5 times higher than in adjacent noncancerous prostate tissue. Laboratory research from the Peking University group also shows that polystyrene microplastics can directly stimulate human prostate cancer cells to multiply. These are striking findings, but both research teams urge the same caution: the studies are small, no one has yet proven that microplastics cause prostate ...
Post a Comment
Read more